{"entity":{"id":"nct04854668","kind":"trial","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","aka":[],"tldr":"A phase 3 trial of Anlotinib, Bevacizumab, CAPOX in colorectal cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.","summary":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT04854668 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 748 participants enrolled, started 2021-05-27 and due to reach its primary completion in 2024-12-31. Interventions recorded: Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04854668","url":"https://clinicaltrials.gov/study/NCT04854668"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["anlotinib","bevacizumab","capox","capecitabine"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04854668-signal-transduct-target-ther-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04854668","phase":"3","setting":"A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","started":"2021-05-27","startedType":"actual","enrolled":748,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04854668/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"paper":[{"id":"paper-nct04854668-signal-transduct-target-ther-2026","kind":"paper","name":"First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial","route":"/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/"}]}}